Halozyme's Upcoming Investor Conferences
Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to make a significant presence at notable investor conferences. The company's executive leadership team will participate in key presentations and meetings, aiming to engage with investors and discuss Halozyme's innovative contributions to the biopharmaceutical industry.
Details of the Conference Participation
The first major event is the Piper Sandler 36th Annual Healthcare Conference. At this conference, Nicole LaBrosse, the Chief Financial Officer, will be presenting. While the exact details of the presentation date are scheduled for December 4, the timing is planned for 10:30 AM PT / 1:30 PM ET. These presentations will adopt a fireside chat format, providing an informal setting to promote better engagement with the audience.
Second Conference Appearance
The second conference that Halozyme will participate in is the 7th Annual Evercore ISI HealthCONx Conference. In this session, Helen Torley, the company's President and Chief Executive Officer, will lead discussions. Scheduled for the same date, December 4, the presentation will commence at 9:30 AM PT / 12:30 PM ET, following a similar format with fireside chats and one-on-one meetings with attendees.
Accessing the Live Webcast
Investors and interested parties can access a live audio webcast of these presentations through the Investor Relations section of Halozyme's website. This interactive experience allows participants to gain insights directly from the leadership team. Additionally, audio replays of the webcasts will remain accessible for a period of 90 days post-conference, allowing wider reach and engagement.
About Halozyme's Innovations
Halozyme is dedicated to improving patient experiences and outcomes through innovative biopharmaceutical solutions. Their pioneering ENHANZE® drug delivery technology, leveraging the proprietary enzyme rHuPH20, is instrumental in facilitating the subcutaneous administration of various therapies and fluids. This technology has already positively impacted over 800,000 patients globally, being utilized across more than 100 markets with eight commercialized products.
Partnerships and Collaborations
The company has established partnerships with leading pharmaceutical giants, including Roche, Takeda, and Pfizer, among others, to promote the use of ENHANZE® technology. These collaborations are driving advancements in drug delivery systems and enhancing the overall treatment experience for patients.
Advancing Drug-Device Combination Products
In addition to its primary focus on drug delivery technology, Halozyme also develops drug-device combination products. These products utilize advanced auto-injector technologies designed to improve convenience, reliability, and patient comfort. They currently have two proprietary products in the market, Hylenex® and XYOSTED®, along with ongoing development programs with various pharmaceutical companies.
Company Headquarters and Contact Information
Halozyme is headquartered in San Diego, with additional offices in Ewing, NJ, and Minnetonka, MN. The facility in Minnetonka serves as its operational base, ensuring the company's advancements in pharmaceuticals are supported by state-of-the-art manufacturing capabilities.
Frequently Asked Questions
What is Halozyme known for?
Halozyme is a biopharmaceutical company recognized for its ENHANZE® drug delivery technology that facilitates subcutaneous drug administration.
Who will be presenting at the upcoming conferences?
Nicole LaBrosse, the CFO, and Helen Torley, the CEO, are the leaders presenting at the Piper Sandler and Evercore ISI conferences respectively.
How can investors listen to the presentations?
Interested parties can access the live audio webcasts through the Investor Relations section of Halozyme's website.
What are the expected benefits of ENHANZE® technology?
ENHANZE® technology aims to improve patient experiences by allowing rapid subcutaneous delivery of medications, reducing treatment burdens.
What commercial products does Halozyme offer?
Halozyme has two proprietary products, Hylenex® and XYOSTED®, and is involved in ongoing development programs with various partners.
